Handok said Thursday that it has signed a strategic partnership agreement with Lilly Korea to exclusively market Cialis, erectile dysfunction, and benign prostatic hyperplasia treatment.

Cialis

Cialis, approved for sales in Korea in 2003, is one of the leading medications sold in the domestic market for erectile dysfunction and benign prostatic hyperplasia, which are typical male urological diseases.

The agreement comes after Handok signed a contract with Lilly Korea to co-promote the treatment in Korea from July 2010 to May 2015.

The company expects Cialis will provide urologists with more treatment options while strengthening its market competitiveness and leadership in the field. Handok had previously accumulated expertise in the urology business with Xatral XL, an antiseptic treatment for prostate, and Toviaz, a bladder treatment for overactive bladder.

“Handok and Lilly Korea had co-marketed Cialis for five years since 2010,” Handok CEO and Chairman Kim Young-jin said. “The company is pleased to market Cialis again, and the company will do its best to market the drug with the exclusive marketing contract.”

Lilly Korea also expressed expectations on the agreement.

“Cialis provides new treatment options for erectile dysfunction and benign prostatic hyperplasia while improving the quality of life for patients,” Lilly Korea CEO Paul Henry Huibers said. “Through this strategic partnership, the two companies will collaborate in delivering quality clinical information to domestic healthcare professionals, while ensuring smooth supply of pharmaceuticals.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>